JP5576591B2 - α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 - Google Patents

α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 Download PDF

Info

Publication number
JP5576591B2
JP5576591B2 JP2007500529A JP2007500529A JP5576591B2 JP 5576591 B2 JP5576591 B2 JP 5576591B2 JP 2007500529 A JP2007500529 A JP 2007500529A JP 2007500529 A JP2007500529 A JP 2007500529A JP 5576591 B2 JP5576591 B2 JP 5576591B2
Authority
JP
Japan
Prior art keywords
day
cancer
ftd
administration
trifluorothymidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2007500529A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2006080327A1 (ja
Inventor
智博 江村
明 三田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5576591(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to JP2007500529A priority Critical patent/JP5576591B2/ja
Publication of JPWO2006080327A1 publication Critical patent/JPWO2006080327A1/ja
Application granted granted Critical
Publication of JP5576591B2 publication Critical patent/JP5576591B2/ja
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007500529A 2005-01-26 2006-01-25 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 Active JP5576591B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007500529A JP5576591B2 (ja) 2005-01-26 2006-01-25 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/042,059 2005-01-26
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
JP2007500529A JP5576591B2 (ja) 2005-01-26 2006-01-25 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (2)

Publication Number Publication Date
JPWO2006080327A1 JPWO2006080327A1 (ja) 2008-06-19
JP5576591B2 true JP5576591B2 (ja) 2014-08-20

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007500529A Active JP5576591B2 (ja) 2005-01-26 2006-01-25 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Country Status (21)

Country Link
EP (1) EP1849470B2 (enExample)
JP (1) JP5576591B2 (enExample)
KR (1) KR101468216B1 (enExample)
AU (1) AU2006209547C1 (enExample)
BE (1) BE2017C028I2 (enExample)
CA (1) CA2594713A1 (enExample)
CY (2) CY2017029I2 (enExample)
DK (1) DK1849470T4 (enExample)
ES (1) ES2630002T5 (enExample)
FI (1) FI1849470T4 (enExample)
FR (1) FR17C1028I2 (enExample)
HU (2) HUE033306T2 (enExample)
LT (2) LT1849470T (enExample)
LU (1) LUC00036I2 (enExample)
NL (1) NL300889I2 (enExample)
PL (1) PL1849470T5 (enExample)
PT (1) PT1849470T (enExample)
RU (1) RU2394581C2 (enExample)
SI (1) SI1849470T2 (enExample)
TW (1) TWI362265B (enExample)
WO (1) WO2006080327A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
SI1849470T2 (sl) 2005-01-26 2024-05-31 Taiho Pharmaceutical Co., Ltd. Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8536188B2 (en) 2007-04-25 2013-09-17 Cyclacel Limited Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
NZ588863A (en) 2008-05-09 2012-08-31 Gruenenthal Chemie Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
CA2723944A1 (en) * 2008-05-15 2009-11-19 Jan Balzarini Anti-cancer combination therapy
ES2718688T3 (es) 2009-07-22 2019-07-03 Gruenenthal Gmbh Forma de dosificación resistente a la manipulación para opioides sensibles a la oxidación
JP5667183B2 (ja) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 加熱溶融押出成型した制御放出性投与剤型
CN103269688A (zh) 2010-09-02 2013-08-28 格吕伦塔尔有限公司 包含无机盐的抗破碎剂型
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
EP2736495B1 (en) 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
NO2736497T3 (enExample) 2011-07-29 2018-01-20
ES2659264T3 (es) * 2011-08-16 2018-03-14 Taiho Pharmaceutical Co., Ltd. Agente antitumoral y método para pronosticar el efecto terapéutico para pacientes con cáncer colorrectal con mutación de KRAS
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
AU2013233226B2 (en) 2012-03-14 2016-05-19 Nisshin Pharma Inc. Sulfur amino acid-containing composition
TR201815502T4 (tr) 2012-04-18 2018-11-21 Gruenenthal Gmbh Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
SG10201608469RA (en) 2012-05-16 2016-11-29 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
WO2014157444A1 (ja) * 2013-03-27 2014-10-02 大鵬薬品工業株式会社 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
EP2979701B1 (en) * 2013-03-27 2020-08-26 Taiho Pharmaceutical Co., Ltd. Antitumor agent including irinotecan hydrochloride hydrate
EP2998742A4 (en) * 2013-05-17 2017-01-18 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
SMT202300167T1 (it) 2013-09-06 2023-07-20 Taiho Pharmaceutical Co Ltd Agente antitumorale e potenziatore dell’effetto antitumorale
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
HK1246173A1 (zh) 2015-04-24 2018-09-07 Grünenthal GmbH 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US11612653B2 (en) 2016-01-08 2023-03-28 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
TWI791430B (zh) * 2016-02-05 2023-02-11 日商大鵬藥品工業股份有限公司 針對具有重度腎功能障礙之癌症患者之治療方法
WO2019124544A1 (ja) 2017-12-22 2019-06-27 大鵬薬品工業株式会社 トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU681321B2 (en) 1995-03-29 1997-08-21 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
AU699728B2 (en) * 1996-09-24 1998-12-10 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
SI1849470T2 (sl) 2005-01-26 2024-05-31 Taiho Pharmaceutical Co., Ltd. Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6011054216; ＥＭＵＲＡ，　Ｔ．　ｅｔ　ａｌ．: ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＪＯＵＲＮＡＬ　ＯＦ　ＭＯＬＥＣＵＬＡＲ　ＭＥＤＩＣＩＮＥ Ｖｏｌ．１３，　Ｎｏ．２, 2004, ｐ．２４９-２５５ *
JPN6011054217; ＢＡＹＥＳ，　Ｍ．　ｅｔ　ａｌ．: Ｍｅｔｈｏｄｓ　Ｆｉｎｄ　Ｅｘｐ　Ｃｌｉｎ　Ｐｈａｒｍａｃｏｌ Ｖｏｌ．２６，　Ｎｏ．１, 2004, ｐ．５３-８４ *
JPN6012005376; 江村智博　他: 第６３回日本癌学会学術総会予稿集 , 2004, ｐ．４６６ *

Also Published As

Publication number Publication date
PL1849470T5 (pl) 2024-06-10
EP1849470A1 (en) 2007-10-31
CY2017029I1 (el) 2018-02-14
EP1849470B1 (en) 2017-06-21
NL300889I1 (nl) 2017-08-14
RU2007132181A (ru) 2009-03-10
SI1849470T1 (sl) 2017-10-30
KR101468216B1 (ko) 2014-12-03
HUS1700032I1 (hu) 2017-09-28
EP1849470A4 (en) 2010-12-08
LT1849470T (lt) 2017-07-25
LUC00036I2 (enExample) 2017-12-01
EP1849470B2 (en) 2024-03-20
LTC1849470I2 (lt) 2019-10-25
CY2017029I2 (el) 2018-02-14
DK1849470T4 (en) 2024-04-02
NL300889I2 (nl) 2018-01-16
FR17C1028I2 (fr) 2018-11-02
AU2006209547B2 (en) 2011-05-26
CA2594713A1 (en) 2006-08-03
CY1119393T1 (el) 2018-02-14
JPWO2006080327A1 (ja) 2008-06-19
HUE033306T2 (hu) 2017-11-28
ES2630002T3 (es) 2017-08-17
ES2630002T5 (es) 2024-09-19
TW200637562A (en) 2006-11-01
WO2006080327A1 (ja) 2006-08-03
LTPA2017024I1 (lt) 2017-08-10
PL1849470T3 (pl) 2017-11-30
AU2006209547C1 (en) 2022-04-07
PT1849470T (pt) 2017-09-22
TWI362265B (en) 2012-04-21
FI1849470T4 (fi) 2024-03-22
RU2394581C2 (ru) 2010-07-20
DK1849470T3 (en) 2017-08-14
FR17C1028I1 (enExample) 2017-09-29
AU2006209547A1 (en) 2006-08-03
BE2017C028I2 (enExample) 2025-09-10
LUC00036I1 (enExample) 2017-10-02
KR20070104559A (ko) 2007-10-26
SI1849470T2 (sl) 2024-05-31

Similar Documents

Publication Publication Date Title
JP5576591B2 (ja) α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
KR20140096375A (ko) 항종양제의 효과 증강제
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
EP2036903B1 (en) Potentiator of radiation therapy
US20090281105A1 (en) Radiotherapy enhancer
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
TWI401085B (zh) Contains cytosine derivatives for continuous intravenous administration with anti-tumor agents
HK1115306A (en) ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR
WO2022014025A1 (ja) 血液がんの新規治療法及び新規治療剤
JPWO2012105486A1 (ja) １日１回隔日投与を特徴とするテガフール含有組成物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120426

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20120426

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120510

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20120515

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120622

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20120626

C141 Inquiry by the administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C141

Effective date: 20131217

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20131217

C54 Written response to inquiry

Free format text: JAPANESE INTERMEDIATE CODE: C54

Effective date: 20140217

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20140430

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20140430

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20140430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140514

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20140701

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20140701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140704

R150 Certificate of patent or registration of utility model

Ref document number: 5576591

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250